Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

Rotator Cuff Injuries Clinical Trial

— IMPACT  

Official title:

Evaluation of Safety and Efficacy of a Resorbable Collagen Implant in Treatment of High Grade PArtial ThiCkness Tears; A Prospective, Multicenter, Randomized, Control Trial (IMPACT Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05444465
• Other study ID #: REGENETEN.2021.04
• Status: Recruiting
• Phase: N/A
• Start date: August 30, 2022
• Est. completion date: June 30, 2027

Study information

• Verified date: May 2024
• Source: Smith & Nephew, Inc.
• Contact: Judith Horner
• Phone: +44 (0) 1482673251
• Email: Judith.Horner[@]smith-nephew.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears.

Description:

The primary objective of this study is to evaluate the functional recovery of patients with high grade (>50%) partial thickness tears at 3 months when treated with either Isolated Bioinductive Repair (IBR) or Completion and Repair (CAR).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 156
• Est. completion date: June 30, 2027
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject must provide written informed consent.
• Subject is > eighteen (18) years of age (no upper limit).
• Subject has an isolated high-grade (>50% or >6mm) (Ellman grade III) partial thickness tear of supraspinatus or supraspinatus with infraspinatus.
• Subject has failed a minimum of 3 months of conservative management for treatment of partial thickness rotator cuff tear.
• Subject willing and able to make all required study visits.
• Subject able to follow instructions and deemed capable of completing all study questionnaires.

Exclusion Criteria:

• Subjects with insufficient tendon tissue quality for management and protection of the tendon injury using the isolated REGENETEN Bioinductive Implant system.
• Subjects where the prescribed Physical Therapy guidelines stated in the protocol are not suitable for their rehabilitation.
• Subjects with Samilson-Prieto osteoarthritis grade 2 and greater.
• Subjects with current or prior infection of the ipsilateral shoulder.
• Subjects with known hypersensitivity to bovine-derived materials.
• Subjects with known inflammatory arthropathy, history of inflammatory arthropathy, chronic joint disease or chronic pain of upper extremities (shoulder(s), arm(s)).
• Subjects with prior shoulder surgery on index shoulder, including subacromial decompression, biceps tenodesis/tenotomy, and acromioclavicular joint (ACJ) excision/distal clavicle excision (DCE).
• Subjects with a planned surgery on the contra-lateral shoulder within the study period.
• Systemic steroid use (oral, IV) or local steroid injection within 3 months of the date of surgery.
• Subjects with a full thickness rotator cuff tear.
• Subjects with a subscapularis tear requiring repair.
• Subjects requiring a concomitant labral fixation procedure, concomitant surgery for bone defects requiring bone implantation or for superior labral tear from anterior to posterior (SLAP).
• Subjects requiring a concomitant os acromiale fixation procedure.
• Subjects with glenohumeral joint instability (multiple dislocations/subluxations).
• Subjects with condition(s) that contraindicate or complicate outcomes of Isolated Bioinductive Repair or completion and repair e.g., > Hamada 3 rotator cuff arthropathy on X-ray, Goutallier atrophy > Grade 3, proximal humeral fracture or scapular fracture, avascular necrosis of the humeral head.
• Subjects with neurologic conditions effecting either upper extremity.
• Subjects who are unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications.
• Subjects who are pregnant or breast feeding.
• Subjects who are currently involved in any injury litigation relating to the index shoulder.
• Subjects with current workers compensation claim.
• Subjects who are enrolled, or plan to enroll, in another clinical trial during this study that would affect the outcomes of this study.
• Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation.
• Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse.
• Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs).
• Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
• Subjects who have participated previously in this clinical trial and who have healed or been withdrawn
• Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Related Conditions & MeSH terms

• Rotator Cuff Injuries

Intervention

Device:
• Isolated Bioinductive Repair
Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant

Procedure:
• Completion and Repair
Standard surgical repair using the 'Completion and Repair' technique.

Locations

Country	Name	City	State
Australia	OrthoSport Victoria	Richmond	Victoria
Canada	Access Orthopaedics	Calgary	Alberta
Canada	Research St. Joseph's	Hamilton	Ontario
Canada	Pan Am Clinic	Winnipeg	Manitoba
Italy	IRCCS Istituto Ortopedico Galeazzi,	Milano
Italy	Fondazione Policlinico Universitario Campus Bio-Medico	Roma
Spain	Hospital Fundación Jiménez Díaz	Madrid
Spain	Hospital Ramón y Cajal	Madrid
United Kingdom	Sulis Hospital	Bath
United Kingdom	North Bristol NHS Trust	Bristol
United Kingdom	Ashford & St Peter's Hospitals NHS Foundation Trust	Chertsey	Surrey
United Kingdom	Northern Care Alliance NHS Foundation Trust	Salford
United States	Memorial Medical Center	Ashland	Wisconsin
United States	Sinai Hospital Baltimore	Baltimore	Maryland
United States	Texas Orthopedic Specialists	Bedford	Texas
United States	Cleveland Clinic - Sports Health	Garfield Heights	Ohio
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	OrthoIllinois LTD	Rockford	Illinois
United States	Harbin Clinic	Rome	Georgia
United States	Houston Methodist The Woodlands	The Woodlands	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Smith & Nephew, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Italy,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Change from baseline to 3 months post-intervention
Secondary	Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Pre-op, 6 weeks, 3, 6, 12 and 24 months
Secondary	Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Pre-Op, 3, 6, 12 and 24 months
Secondary	Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Pre-Op, 6 weeks, 3, 12 and 24 months
Secondary	EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS & index scores	To assess the subject's health state. The EQ-5D-5L is composed of the EQ- 5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS).; The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. For instance, 'slight problems' (e.g. 'I have slight problems in walking about') is always coded as '2'. The digits for the five dimensions are combined in a 5-digit code. The EQ- 5D-5L index value is derived by using the vendor supplied calculator to convert each 5-digit EQ- 5D-5L profile.; The EQ VAS corresponds to a 20 cm vertical, visual analogue scale ranging from 'the best health you can imagine' to 'the worst health you can imagine'.; A higher number is a better outcome.	Pre-Op, 3 and 6 weeks, 3, 6, 12 and 24 months
Secondary	Change in Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Change from Pre-op to 6 weeks, 3, 6, 12 and 24 months
Secondary	Change in Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Secondary	Change in Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Secondary	Percent Achieving Minimal Clinically Important Difference (MCID) for Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Pre-Op, 3, 6, 12 and 24 months
Secondary	Percent Achieving MCID for Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Pre-op, 6 weeks, 3, 6, 12 and 24 months
Secondary	Percent Achieving MCID for Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Pre-Op, 6 weeks, 3, 12 and 24 months
Secondary	Patient Satisfaction	Comprise of 2 questions: Overall, I am satisfied with the outcome of my surgery; I would recommend the procedure to a friend.; Question rated by the patient with Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree.	6 weeks, 3, 6, 12 and 24 months
Secondary	Pain, Visual analog scale (VAS) Score	Pain is assessed on a 100-point scale ranging from 0 to 100, with zero (0) representing no pain and 100 representing the worst pain imaginable.	Pre-Op, 3 and 6 weeks, 3, 12 and 24 months
Secondary	MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Sugaya Score	The Sugaya score is classified into 5 categories: Type I to Type V. Type I indicates sufficient thickness with homogenously low intensity. Type II indicates sufficient thickness with partial high intensity. Type III indicates insufficient thickness without discontinuity. Type IV indicates presence of a minor discontinuity, suggesting a small full-thickness tear. Type V indicates the presence of a major discontinuity, suggesting a medium or large full-thickness tear.	12 months
Secondary	MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of percent filling	Percent tissue infil is graded at site of original tear and classified as 0% to < 25%, 25% to < 50%, 50% to < 75%, 75% to < 100% and 100%.	12 months
Secondary	MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of the signal intensity pattern	The Signal Intensity Pattern will be graded into 3 categories. Type I: Heterogeneous high signal intensity with fluid-like bright foci, Type II: Heterogeneous high signal intensity without fluid-like bright foci, Type III: Heterogeneous or homogeneous low signal intensity.	12 months
Secondary	MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Rotator cuff tendon thickness	Tendon thickness will be measured in millimeters (mm).	12 months
Secondary	MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Goutallier classification	The Goutallier classification will be used to classify the fatty infiltration of the rotator cuff. The Goutallier classification ranges from a grade of 0 indicating a completely normal muscles without any fatty streaks to a grade of 4 which indicates that more fat than muscle is present.	12 months
Secondary	Incidence of Revision Surgery	Number of subjects requiring revision surgery	1, 3 and 6 weeks, 3, 6, 12 and 24 months
Secondary	Time to return to work	Number of weeks taken to return to work following surgery	Up to 24 months
Secondary	Time to return to driving	Number of weeks taken to return to driving following surgery	Up to 24 months
Secondary	Time to return to sports	Number of weeks taken to return to sport following surgery	Up to 24 months
Secondary	Total operative time	Time expressed in minutes	Inter-operative time
Secondary	Physical Therapy Utilization	Number visits following index surgery	Up to 24 months
Secondary	Cumulative days of opioid use	Self-reported opioid use diary completed by the patient on a daily basis, from day 0-14, documenting opioid use. Consumption daily (YES/NO) x14 days, 'Have you taken any opioid medication today for shoulder pain?'	Day 1-14
Secondary	Duration of shoulder immobilization following index surgery	Number of days	1, 3 and 6 weeks, 3 months